Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/27081| Title: | Changes in prescribing habits for the treatment of metastatic renal clear cell carcinoma (mRCC) in Australia. | Austin Authors: | Balasubramanian, Adithya ;Qu, Liang G ;Weickhardt, Andrew J ;Bolton, Damien M ;Perera, Marlon | Affiliation: | Olivia Newton-John Cancer Wellness and Research Centre Department of Medical Oncology, Monash Health, Melbourne, Victoria, Australia Surgery (University of Melbourne) Department of Urology, Western Health, University of Melbourne, Victoria, Australia Austin Health |
Issue Date: | Jul-2021 | Publication information: | Internal Medicine Journal 2021; 51(7): 1173-1177 | Abstract: | The availability of efficacious systemic therapies for metastatic clear cell renal cell carcinoma has heralded improved survival for Australians. The Pharmaceutical Benefits Schedule registry was interrogated to assess nation-wide prescribing patterns. Sunitinib remained the most commonly prescribed agent. Prescribing rates were significantly lower in Northern Territory than in other states, raising questions of disparities in access to care. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/27081 | DOI: | 10.1111/imj.15419 | ORCID: | 0000-0002-1138-6389 | Journal: | Internal Medicine Journal | PubMed URL: | 34278692 | Type: | Journal Article | Subjects: | immunotherapy metastatic oncology renal cell cancer systemic therapies tyrosine kinase inhibitors |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.